<DOC>
	<DOCNO>NCT01772823</DOCNO>
	<brief_summary>Approximately 200 HIV-uninfected young men sex men ( YMSM ) high risk acquire HIV infection , age 18-22 year , inclusive , recruit across participate Adolescent Medicine Trials Units ( AMTU ) . The behavioral intervention assign level site , include Many Men , Many Voices ( 3MV ) Personalized Cognitive Counseling ( PCC ) . Subjects first complete behavioral intervention offer respective site provide open label emtricitabine ( FTC ) /tenofovir ( TDF ) ( Truvada® ) PrEP . Behavioral biomedical data collect baseline 0 , 4 , 8 , 12 , 24 , 36 48 week . Any subject become HIV infected course study discontinue study agent follow additional 24 week study visit HIV infection confirm . Those subject meet specific bone renal criterion Week 48 visit 24-Week HIV Seropositive visit follow additional 48 week Extension Phase closely monitor longer-term outcome potential concern .</brief_summary>
	<brief_title>An Open Label Demonstration Project Phase II Safety Study Pre-Exposure Prophylaxis</brief_title>
	<detailed_description>The primary objective study provide additional safety data regard FTC/TDF ( Truvada® ) use PrEP YMSM , examine acceptability , pattern use , rate adherence , measure level drug exposure pattern risk behavior YMSM provide open label FTC/TDF ( Truvada® ) . The study also examine information regard safety efficacy PrEP prior study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Willing able provide write informed consent ; Male gender birth ; Age 18 year 0 day 22 year 364 day , inclusive , time sign informed consent ; Self report evidence high risk acquire HIV infection include least one following : At least one episode unprotected anal intercourse HIVinfected male partner male partner unknown HIV status last 6 month ; Anal intercourse 3 male sex partner last 6 month ; Exchange money , gift , shelter , drug anal sex male partner last 6 month ; Sex male partner sexually transmit infection ( STI ) last 6 month screen ; Sexual partner HIVinfected man condom consistently use last 6 month ; At least one episode anal intercourse condom break slip last 6 month ; Tests HIV antibody negative time screen ; Willing provide locator information study staff ; Willing take preexposure prophylaxis ( PrEP ) ; Willing participate behavioral intervention ; Reports intention relocate Adolescent Medicine Trial Unit ( AMTU ) study area course study ; Does job obligation would require long absence AMTU study area ( great 4 week time ) . Appears visibly distraught presence active serious psychiatric symptom ( e.g. , active hallucination , suicidal , homicidal , exhibit violent behavior ) time consent ; Intoxicated influence alcohol drug time consent ; Any significant uncontrolled , active chronic disease process , judgment site investigator , would make participation study inappropriate . ( Appropriately manage condition , like wellcontrolled diabetes , would preclude enrollment ; site encourage contact Adolescent Medicine Trials Network HIV/AIDS Interventions ( ATN ) 110 Protocol Team difficulty make judgment . ) ; History bone fracture explain trauma ; Acute chronic hepatitis B infection indicate positive hepatitis B surface antigen ( sAg ) test time screen ; Confirmed renal dysfunction ( Creatinine Clearance ( CrCl ) &lt; 75 ml/min , serum creatinine ≥ upper limit normal ( ULN ) , history renal parenchymal disease presence one kidney time screen ; Confirmed ≥ Grade 2 hypophosphatemia time screen ; Confirmed ≥ Grade 2 hematologic system abnormality ( White Blood Count ( WBC ) , Absolute Neutrophil Count ( ANC ) , hemoglobin , platelet ) time screen ; Confirmed ≥ Grade 2 hepatobiliary system abnormality ( Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , bilirubin ) time screen ; Confirmed proteinuria indicate urine dipstick result ≥ 1+ time screening , regardless urine protein creatinine ratio ( UP/C ) ; UP/C &gt; 0.37 g/g time screening , regardless urine dipstick protein result ; Confirmed normoglycemic glucosuria indicate urine dipstick result ≥ 1+ presence normal serum glucose ( &lt; 120 mg/dL ) time screen ; A confirm Grade ≥ 3 toxicity screening evaluation ; Known allergy/sensitivity study agent component ; Concurrent participation HIV vaccine study investigational drug study , include oral topical PrEP ( microbicide ) study ; Use disallow medication ; Inability understand spoken English .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV , PrEP , FTC/TDF , Truvada</keyword>
</DOC>